NEWS

WIRES

OTHER

Bryan Luman Joins Zynex Medical as Director of Marketing

Zynex Medical , strengthens its management team with the addition of Mr. Bryan Luman as Director of Marketing. Mr. Luman brings Zynex a very extensive marketing and business development experience in various medical and technical devices. He will be initiating an aggressive NeuroMove(TM) marketing campaign, beginning this quarter. The goal for this campaign will be to substantially increase NeuroMove(TM) sales over the next 18-24 months.

Most recently held the position as VP of Sales and Marketing with BSI2000, a healthcare software company. He received his undergraduate degree from the University of North Texas and an MBA in Business Administration from the University of Phoenix.

Thomas Sandgaard, CEO of Zynex Medical, stated, "We are extremely excited to have Bryan join our team. With his extensive experience in this field, I believe Bryan will help us fulfill the goals that we have set for the Company."

ABOUT ZYNEX MEDICAL, INC.:

Since 1996, Zynex has been a leading provider of relief for patients with functional disability through the creation, distribution and marketing of the highest quality electrotherapy products available today. Zynex continually strives to uphold its mission to improve the quality of life of patients suffering from debilitating pain or illness by providing the highest technology and service standards in the electrotherapy industry. Utilizing various methods of non-invasive muscle stimulation and state-of-the-art electromyography technology, Interferential Current (IFC) and Transcutaneous Electrical Nerve Stimulation (TENS), Zynex offers patients a new lease on life through increased mobility and independence.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.